EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Serum fibroblast growth factor-23 concentration in dogs with myxomatous mitral valve disease

Naoki Iwasa iD, Mamu Shimizu iD, Tomoko Okamoto iD, Hiroto Kosuga iD, Nayu Morikita iD, Mifumi Kawabe iD, Munetaka Iwata iD, Kazuhiro Watanabe iD, Yui Kobatake iD, Satoshi Takashima iD, Naohito Nishii iD

Journal of Veterinary Internal Medicine · 01.09.2026 · 40 (5)

DOI: 10.1093/jvimsj/aalag265 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Veterinary Internal Medicine, online erschienen am 29.10.2026. Verfasst von Naoki Iwasa und 10 weiteren Autor:innen. Beteiligte Einrichtung: Hashima Animal Hospital, Gifu 501-6625, Japan. Hauptthemen laut MEDLINE: Dog Diseases, Fibroblast Growth Factors, Heart Valve Diseases, Mitral Valve Insufficiency. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Circulating fibroblast growth factor-23 (FGF-23) is primarily a kidney-related biomarker, but also may be influenced by cardiovascular remodeling and hemodynamic load. Hypothesis/Objectives Verify whether serum FGF-23 concentration increases with myxomatous mitral valve disease (MMVD) severity. Animals Forty-two client-owned dogs with MMVD without overt kidney disease.

Methods

Retrospective cross-sectional study to evaluate serum FGF-23, N-terminal pro-B-type natriuretic peptide (NT-proBNP), atrial natriuretic peptide (ANP), blood urea nitrogen (BUN), creatinine (Cr), and symmetric dimethylarginine (SDMA) concentrations. Imaging variables included vertebral heart score (VHS), vertebral left atrial size (VLAS), left atrial-to-aortic root ratio (LA/Ao), normalized left-ventricular internal diameter in diastole (LVIDDN), and diastolic transmitral E-wave velocity (E-vel). Differences among American College of Veterinary Internal Medicine stages were analyzed using the Kruskal–Wallis test with Bonferroni-adjusted pairwise comparisons. Correlations were analyzed using Spearman’s correlation. Multivariable linear regression analysis was performed to identify factors associated with serum FGF-23 concentration.

Results

Dogs with ACVIM stages C and D had higher serum FGF-23 concentrations than those with stages B1 and B2 (P < .05). Serum FGF-23 concentrations were positively correlated with VLAS (rs = 0.500, P < .01), ANP (rs = 0.455, P < .01), LA/Ao (rs = 0.384, P < .05), E-vel (rs = 0.372, P < .05), and NT-proBNP (rs = 0.366, P < .05). ACVIM stage was significantly associated with serum FGF-23 concentration after adjustment for serum Cr concentration and loop diuretic use. Conclusions and clinical importance The potential influence of MMVD should be considered when interpreting increased circulating FGF-23 concentrations in dogs with MMVD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dog DiseasesFibroblast Growth FactorsHeart Valve DiseasesMitral Valve InsufficiencyAnimalsDogsFemaleMaleAtrial Natriuretic FactorCross-Sectional StudiesRetrospective StudiesFibroblast Growth Factor-23Natriuretic Peptide, BrainPeptide FragmentsBiomarkersArginineCreatinineBlood Urea Nitrogen

Stichwörter der Autor:innen

ACVIM stagebiomarkersdogsfibroblast growth factor-23left atrial enlargementmyxomatous mitral valve disease

Substanzen

Fibroblast Growth FactorsAtrial Natriuretic FactorFibroblast Growth Factor-23Natriuretic Peptide, BrainPeptide FragmentsBiomarkersArgininepro-brain natriuretic peptide (1-76)Creatininesymmetric dimethylarginine

Autor:innen und Institutionen

  • Hashima Animal Hospital, Gifu 501-6625, Japan.
  • Joint Department of Veterinary Medicine, Faculty of Applied Biological Sciences, Gifu University, Gifu 501-1193, Japan.
  • Gifu University Animal Medical Center, Gifu 501-1193, Japan.
  • Orchid Animal Oncology and Orthopedic Center, Tokyo 120-0035, Japan.

ORCID-Profile: Naoki Iwasa, Mamu Shimizu, Tomoko Okamoto, Hiroto Kosuga, Nayu Morikita, Mifumi Kawabe, Munetaka Iwata, Kazuhiro Watanabe, Yui Kobatake, Satoshi Takashima, Naohito Nishii

Zitieren

APA

Iwasa, N., Shimizu, M., Okamoto, T., Kosuga, H., Morikita, N., Kawabe, M., Iwata, M., Watanabe, K., Kobatake, Y., Takashima, S., & Nishii, N. (2026). Serum fibroblast growth factor-23 concentration in dogs with myxomatous mitral valve disease. Journal of Veterinary Internal Medicine, 40(5). https://doi.org/10.1093/jvimsj/aalag265

Vancouver

Iwasa N, Shimizu M, Okamoto T, Kosuga H, Morikita N, Kawabe M, et al. Serum fibroblast growth factor-23 concentration in dogs with myxomatous mitral valve disease. Journal of Veterinary Internal Medicine. 2026;40(5). doi:10.1093/jvimsj/aalag265

BibTeX
@article{Iwasa2026,
  author = {Iwasa, Naoki and Shimizu, Mamu and Okamoto, Tomoko and Kosuga, Hiroto and Morikita, Nayu and Kawabe, Mifumi and Iwata, Munetaka and Watanabe, Kazuhiro and Kobatake, Yui and Takashima, Satoshi and Nishii, Naohito},
  title = {Serum fibroblast growth factor-23 concentration in dogs with myxomatous mitral valve disease},
  journal = {Journal of Veterinary Internal Medicine},
  year = {2026},
  volume = {40},
  number = {5},
  doi = {10.1093/jvimsj/aalag265}
}
Kostenlos starten →